Skip to main content
. 2015 Oct 16;21(1):10.18553/jmcp.2015.21.1.46. doi: 10.18553/jmcp.2015.21.1.46

TABLE 2.

Base-Case Results

Pazopanib Sunitinib Difference
Effectiveness (not discounted), $
  Progression-free life-years 1.130 1.147 -0.017
  Postprogression life-years 0.993 0.921 0.072
  Life-years 2.122 2.068 0.054
  QALYs 1.393 1.301 0.092
Effectiveness (discounted), $
  Progression-free life-years 1.113 1.130 -0.016
  Postprogression life-years 0.957 0.887 0.069
  Life-years 2.070 2.017 0.053
  QALYs 1.361 1.270 0.090
Costs (discounted), $
  Study medication 68,209 74,473 -6,264
  Administration/dispensing 1,008 707 301
  Other costs associated with pazopanib and sunitinib treatmenta 9,147 12,381 -3,234
  Preprogression routine follow-up 29,926 30,365 -439
  Postprogression routine follow-up 46,269 43,460 2,809
  Total 154,559 161,387 -6,828
Incremental cost per QALY gained, $ Dominant
NMB by threshold for cost-effectiveness, $
  $50,000 per QALY gained 11,343
  $100,000 per QALY gained 15,857
  $200,000 per QALY gained 24,886

a Based on medical resource utilization data from the Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib (COMPARZ) study.

NMB = net monetary benefit; QALY = quality-adjusted life-year.